Ivor Elrifi Acquires 83,807 Shares of Tiziana Life Sciences (NASDAQ:TLSA) Stock

Tiziana Life Sciences Ltd (NASDAQ:TLSA) CEO Ivor Elrifi purchased 83,807 shares of the business’s stock in a transaction that occurred on Tuesday, August 4th. The stock was acquired at an average price of $0.97 per share, for a total transaction of $81,292.79. Following the acquisition, the chief executive officer directly owned 4,556,068 shares of the company’s stock, valued at $4,419,385.96. This trade represents a 1.87% increase in their position. The purchase was disclosed in a document filed with the SEC, which is available through this link.

Ivor Elrifi also recently made the following trade(s):

• On Wednesday, August 5th, Ivor Elrifi purchased 237,616 shares of Tiziana Life Sciences stock. The shares were acquired at an average cost of $1.00 per share, for a total transaction of $237,616.00.
• On Monday, August 3rd, Ivor Elrifi acquired 667,000 shares of Tiziana Life Sciences stock. The shares were acquired at an average price of $1.00 per share, with a total value of $667,000.00.

Tiziana Life Sciences Price Performance

Shares of Tiziana Life Sciences stock traded up $0.04 during trading hours on Thursday, hitting $1.02. The company’s stock had a trading volume of 434,962 shares, compared to its average volume of 240,434. The business has a fifty day moving average of $1.15 and a 200 day moving average of $1.30. Tiziana Life Sciences Ltd has a 1-year low of $0.87 and a 1-year high of $2.53.

Analysts Set New Price Targets

Several research analysts have commented on the company. Wall Street Zen lowered Tiziana Life Sciences from a “hold” rating to a “sell” rating in a research report on Saturday, April 18th. Weiss Ratings downgraded Tiziana Life Sciences from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 29th. Finally, Zacks Research upgraded Tiziana Life Sciences to a “hold” rating in a research note on Tuesday, July 14th. One equities research analyst has rated the stock with a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Reduce”.

Hedge Funds Weigh In On Tiziana Life Sciences

A number of institutional investors and hedge funds have recently added to or reduced their stakes in TLSA. Cubist Systematic Strategies LLC purchased a new position in Tiziana Life Sciences in the first quarter valued at about $25,000. Rachor Investment Advisory Services LLC acquired a new stake in Tiziana Life Sciences in the fourth quarter valued at $25,000. Bison Wealth LLC bought a new position in Tiziana Life Sciences during the 4th quarter valued at $30,000. HRT Financial LP bought a new position in Tiziana Life Sciences during the 4th quarter valued at $36,000. Finally, Marshall Wace LLP acquired a new position in Tiziana Life Sciences during the 2nd quarter worth $39,000.

About Tiziana Life Sciences

Tiziana Life Sciences plc (NASDAQ: TLSA) is a clinical-stage biotechnology company focused on the development of novel therapeutics in the fields of oncology, immunology and infectious diseases. Headquartered in London, with research and development operations in Cambridge, Massachusetts, the company advances both small-molecule inhibitors and monoclonal antibody candidates designed to modulate immune pathways and target tumor growth.

The company’s lead small‐molecule program, milciclib, is an oral cyclin‐dependent kinase inhibitor currently in Phase II clinical trials for hepatocellular carcinoma and certain neuroendocrine tumors.